Medicine & Life Sciences
Acute Myeloid Leukemia
50%
Acute Promyelocytic Leukemia
8%
Agammaglobulinaemia Tyrosine Kinase
10%
Allogeneic Cells
16%
Azacitidine
16%
B-Cell Chronic Lymphocytic Leukemia
98%
B-Lymphocytes
25%
blinatumomab
38%
Bone Marrow
10%
Cell- and Tissue-Based Therapy
9%
Chimeric Antigen Receptors
15%
Cladribine
9%
Cyclophosphamide
18%
Cytarabine
20%
Cytogenetics
9%
Dasatinib
19%
Decitabine
14%
Dexamethasone
11%
Doxorubicin
10%
Drug Therapy
23%
fludarabine
15%
GATA2 Deficiency
10%
High-Throughput Nucleotide Sequencing
8%
Idarubicin
10%
Inotuzumab Ozogamicin
34%
IPI-145
10%
Leukemia
20%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
16%
Leukemia, Myeloid, Chronic Phase
9%
Mutation
16%
Myelodysplastic Syndromes
10%
Neoplasms
11%
PCI 32765
52%
Philadelphia Chromosome
49%
ponatinib
33%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
100%
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8%
Progression-Free Survival
13%
Protein-Tyrosine Kinases
17%
Recurrence
10%
Residual Neoplasm
16%
Rituximab
16%
Safety
9%
Stem Cell Transplantation
12%
Survival
27%
Survival Rate
11%
T-Lymphocytes
13%
Therapeutics
26%
venetoclax
62%
Vincristine
15%